Please provide your email address to receive an email when new articles are posted on . Teprotumumab reduces proptosis by 2 mm or more for most adults with long-standing thyroid eye disease and low ...
Please provide your email address to receive an email when new articles are posted on . CHICAGO — Pretreatment evaluation of fat-to-muscle ratio in thyroid eye disease will allow for the best ...
DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) today announced new pooled efficacy data from the Phase 2 and 3 clinical trials of TEPEZZA™ (teprotumumab-trbw) showing that the ...
Credit: Getty Images. Tepezza is a human insulin-like growth factor-1 receptor inhibitor. Tepezza ® (teprotumumab-trbw) significantly reduced proptosis in adults with chronic thyroid eye disease (TED) ...
This story is part of a series on the current progression in Regenerative Medicine. This piece is part of a series dedicated to the eye and improvements in restoring vision. In 1999, I defined ...
Findings from THRIVE showed treatment with veligrotug led to statistically significant improvements in the signs and symptoms of TED. Topline data were announced from a phase 3 study evaluating ...
Study findings presented at the American Society of Ophthalmic Plastic & Reconstructive Surgery's 2021 Fall Scientific Symposium detail the benefits of teprotumumab for thyroid eye disease. New ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results